← Back to Search

Unknown

AR882 Multiple Dose for Kidney Failure

Phase 1
Waitlist Available
Research Sponsored by Arthrosi Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 21 days
Awards & highlights

Study Summary

This study is evaluating whether a drug may be safe for use in patients with kidney disease.

Eligible Conditions
  • Kidney Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~21 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 21 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
AUC for plasma following multiple doses of AR882 in subjects with renal impairment and normal renal function
Amount excreted (Ae) into urine following a single dose of AR882 in subjects with renal impairment and normal renal function
Area under the curve (AUC) for plasma following a single dose of AR882 in subjects with renal impairment and normal renal function
+7 more
Secondary outcome measures
Incidence of Adverse Events, changes in laboratory, electrocardiogram, and vital signs following a single dose of AR882 in subjects with renal impairment and normal renal function
Incidence of Adverse Events, changes in laboratory, electrocardiogram, and vital signs following multiple doses of AR882 in subjects with renal impairment and normal renal function

Trial Design

2Treatment groups
Experimental Treatment
Group I: Renal ImpairmentExperimental Treatment2 Interventions
Subjects with various degrees of renal impairment
Group II: Normal Renal FunctionExperimental Treatment2 Interventions
Subjects with normal renal function
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AR882 Single Dose
2021
Completed Phase 1
~50
AR882 Multiple Dose
2021
Completed Phase 1
~50

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Iqvia Pty LtdIndustry Sponsor
107 Previous Clinical Trials
170,022 Total Patients Enrolled
Arthrosi TherapeuticsLead Sponsor
6 Previous Clinical Trials
312 Total Patients Enrolled
Vijay Hingorani, MD, PhD, MBAStudy DirectorArthrosi Therapeutics
2 Previous Clinical Trials
126 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment
2021. "Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04646889.
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top